Log in

Relevant bibliographies by topics / Disease progression score / Journal articles

To see the other types of publications on this topic, follow the link: Disease progression score.

Journal articles on the topic 'Disease progression score'

Author: Grafiati

Published: 25 May 2024

Last updated: 19 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Disease progression score.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

O’Charoen, Sirimon, Katherine Gilpin, Tara Fehlmann, et al. "DEVELOPMENT OF NOVEL PROGRESSION SCORE TO QUANTIFY DISEASE PROGRESSION IN CROHN’S DISEASE." Inflammatory Bowel Diseases 31, Supplement_1 (2025): S53. https://doi.org/10.1093/ibd/izae282.126.

Full text

Abstract:

Abstract BACKGROUND AND AIMS Crohn’s disease (CD) is a progressive disease that often leads to complications requiring pharmaceutical and surgical interventions. There is no standard definition of disease progression. The Crohn’s & Colitis Foundation IBD Plexus program formed a Workgroup to address unmet need for CD patients who progress despite treatment. The study aimed to develop a CD progression score using longitudinal, registry data linked to claims and assess if real world data allows for categorizing CD patients with progression. METHODS CD patients in the IBD Plexus and HealthVeri

APA, Harvard, Vancouver, ISO, and other styles

2

O’Charoen, Sirimon, Katherine Gilpin, Tara Fehlmann, et al. "DEVELOPMENT OF NOVEL PROGRESSION SCORE TO QUANTIFY DISEASE PROGRESSION IN CROHN’S DISEASE." Gastroenterology 168, no. 3 (2025): S76. https://doi.org/10.1053/j.gastro.2025.01.168.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Shan, Guogen, Xinlin Lu, Zhigang Li, Jessica Z. K. Caldwell, Charles Bernick, and Jeffrey Cummings. "ADSS: A Composite Score to Detect Disease Progression in Alzheimer’s Disease." Journal of Alzheimer's Disease Reports 8, no. 1 (2024): 307–16. http://dx.doi.org/10.3233/adr-230043.

Full text

Abstract:

Background: Composite scores have been increasingly used in trials for Alzheimer’s disease (AD) to detect disease progression, such as the AD Composite Score (ADCOMS) in the lecanemab trial. Objective: To develop a new composite score to improve the prediction of outcome change. Methods: We proposed to develop a new composite score based on the statistical model in the ADCOMS, by removing duplicated sub-scales and adding the model selection in the partial least squares (PLS) regression. Results: The new AD composite Score with variable Selection (ADSS) includes 7 cognitive sub-scales. ADSS can

APA, Harvard, Vancouver, ISO, and other styles

4

Roussanov, Bisser V., Jeremy M. G. Taylor, and Janis V. Giorgi. "Calculation and use of an HIV-1 disease progression score." AIDS 14, no. 17 (2000): 2715–22. http://dx.doi.org/10.1097/00002030-200012010-00011.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Pihlstrøm, Lasse, Kristina Rebekka Morset, Espen Grimstad, Valeria Vitelli, and Mathias Toft. "A cumulative genetic risk score predicts progression in Parkinson's disease." Movement Disorders 31, no. 4 (2016): 487–90. http://dx.doi.org/10.1002/mds.26505.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Ungaro, R., R. Jordan, C. Yzet, et al. "P240 CDEIS score of 2 is optimal cut-off associated with lower risk of disease progression in early Crohn’s disease: Data from the CALM study." Journal of Crohn's and Colitis 14, Supplement_1 (2020): S264—S266. http://dx.doi.org/10.1093/ecco-jcc/jjz203.369.

Full text

Abstract:

Abstract Background The optimal endoscopic target in early Crohn’s disease (CD) that limits long-term disease complications is unknown. Methods We analysed medical records from patients who had follow-up data since the end of CALM. Patients with Crohn’s disease endoscopic index of severity (CDEIS) scores at the end of CALM were included. The primary outcome was a composite of major adverse outcomes reflecting CD progression: new internal fistula/abscess, stricture, perianal fistula/abscess, CD hospitalisation, or CD surgery since the end of CALM. We compared median CDEIS and per cent improveme

APA, Harvard, Vancouver, ISO, and other styles

7

Kataoka, Hiroshi, and Kazuma Sugie. "Association between Fatigue and Hoehn-Yahr Staging in Parkinson’s Disease: Eight-Year Follow-Up Study." Neurology International 13, no. 2 (2021): 224–31. http://dx.doi.org/10.3390/neurolint13020023.

Full text

Abstract:

The severity of Parkinson’s disease (PD) is developed by multifactorial factors. Falls can worsen disease severity. We previously found that frontal assessment battery (FAB) score was associated with a higher risk of future falls. This eight-year follow-up study aimed to verify whether factors including low FAB score can be the risk of PD progression based on the Hoehn and Yahr scale. In total, 95 patients were initially enrolled in this research and 45 were included in the final follow-up. Then, the cohort was classified into patients with and without disease progression, defined by upgrade o

APA, Harvard, Vancouver, ISO, and other styles

8

Shi, Manman, Yan Ouyang, Mingxin Yang, et al. "IgA Nephropathy Susceptibility Loci and Disease Progression." Clinical Journal of the American Society of Nephrology 13, no. 9 (2018): 1330–38. http://dx.doi.org/10.2215/cjn.13701217.

Full text

Abstract:

Background and objectivesAt least 20 susceptibility loci of IgA nephropathy have been identified by genome-wide association studies to date. Whether these loci were associated with disease progression is unclear.Design, setting, participants, & measurementsWe enrolled 613 adult patients with IgA nephropathy for a follow-up of ≥12 months. All 20 IgA nephropathy susceptibility loci were selected and their tag single nucleotide polymorphisms (SNPs) were genotyped. After strict quality control, 16 SNPs and 517 patients with IgA nephropathy were eligible for subsequent analysis. Progression was

APA, Harvard, Vancouver, ISO, and other styles

9

Moore, Ursula, Marni Jacobs, Meredith K. James, et al. "Assessment of disease progression in dysferlinopathy." Neurology 92, no. 5 (2019): e461-e474. http://dx.doi.org/10.1212/wnl.0000000000006858.

Full text

Abstract:

ObjectiveTo assess the ability of functional measures to detect disease progression in dysferlinopathy over 6 months and 1 year.MethodsOne hundred ninety-three patients with dysferlinopathy were recruited to the Jain Foundation's International Clinical Outcome Study for Dysferlinopathy. Baseline, 6-month, and 1-year assessments included adapted North Star Ambulatory Assessment (a-NSAA), Motor Function Measure (MFM-20), timed function tests, 6-minute walk test (6MWT), Brooke scale, Jebsen test, manual muscle testing, and hand-held dynamometry. Patients also completed the ACTIVLIM questionnaire.

APA, Harvard, Vancouver, ISO, and other styles

10

Jönsson, Linus, Milana Ivkovic, Ron Handels, et al. "OP142 Progression Analysis Versus Traditional Methods To Quantify Slowing Of Disease Progression In Alzheimer’s Disease." International Journal of Technology Assessment in Health Care 39, S1 (2023): S42. http://dx.doi.org/10.1017/s0266462323001435.

Full text

Abstract:

IntroductionNew statistical methodology, known as progression models for repeated measures (PMRM), can estimate the slowing of progression (percentage slowing or time delay) of Alzheimer’s disease from trial data on disease-modifying therapies. We compared the PMRM methodology with mixed models for repeated measures (MMRM) and Cox time-to-event analysis on simulated trial data with respect to their power and interpretability of estimates.MethodsTwo novel models were included: PMRM (estimating slowing of progression and allowing different rates across visits) and proportional-slowing PMRM. Clin

APA, Harvard, Vancouver, ISO, and other styles

11

Viticchi, Giovanna, Lorenzo Falsetti, Laura Buratti, et al. "Framingham risk score can predict cognitive decline progression in Alzheimer's disease." Neurobiology of Aging 36, no. 11 (2015): 2940–45. http://dx.doi.org/10.1016/j.neurobiolaging.2015.07.023.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Ravindran, J., C. Cavill, C. Balakrishnan, S. M. Jones, E. Korendowych, and N. J. McHugh. "A modified sharp score demonstrates disease progression in established psoriatic arthritis." Arthritis Care & Research 62, no. 1 (2010): 86–91. http://dx.doi.org/10.1002/acr.20018.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Preziosa, Paolo, Elisabetta Pagani, Alessandro Meani, et al. "Slowly Expanding Lesions Predict 9-Year Multiple Sclerosis Disease Progression." Neurology - Neuroimmunology Neuroinflammation 9, no. 2 (2022): e1139. http://dx.doi.org/10.1212/nxi.0000000000001139.

Full text

Abstract:

Background and ObjectivesChronic active lesions contribute to multiple sclerosis (MS) severity, but their association with long-term disease progression has not been evaluated yet. White matter (WM) lesions showing linear expansion over time on serial T1- and T2-weighted scans (i.e., slowly expanding lesions [SELs]) have been proposed as a marker of chronic inflammation. In this study, we assessed whether SEL burden and microstructural abnormalities were associated with Expanded Disability Status Scale (EDSS) score worsening and secondary progressive (SP) conversion at 9.1-year follow-up in pa

APA, Harvard, Vancouver, ISO, and other styles

14

Koc, G. H., M. R. Kok, J. Luime, et al. "OP0065 THE DETERMINANTS OF RADIOGRAPHIC PROGRESSION IN EARLY PSA PATIENTS." Annals of the Rheumatic Diseases 82, Suppl 1 (2023): 44.2–45. http://dx.doi.org/10.1136/annrheumdis-2023-eular.5638.

Full text

Abstract:

BackgroundPsoriatic arthritis (PsA) is inflammatory arthritis associated with a progressive erosive disease which had been reported in more than one-half of patients with PsA and is often associated with functional impairment [1]. Despite advances in diagnosis and therapy, radiographic structural damage is still prevalent in PsA. To shed light on this topic, we studied which clinical characteristics determine radiographic progression using conventional radiography.ObjectivesOur aim is to assess baseline clinical parameters as determinants for radiographic progression in early PsA patients at 2

APA, Harvard, Vancouver, ISO, and other styles

15

Pilat, I. O., and I. M. Skrypnyk. "IMPACT OF CORONARY ARTERY DISEASE ON STEATOTIC LIVER DISEASE PROGRESSION." Актуальні проблеми сучасної медицини: Вісник Української медичної стоматологічної академії 24, no. 2 (2024): 44–48. http://dx.doi.org/10.31718/2077-1096.24.2.44.

Full text

Abstract:

Introduction. Metabolic dysfunction-associated steatotic liver disease and coronary artery disease often exacerbate each other, leading to a more severe course of both conditions. The aim of this study is to evaluate the role of coronary artery disease in dislipidemia and liver fibrosis progression in patients with metabolic dysfunction-associated steatotic liver disease. Materials and methods. Forty-six patients with metabolic dysfunction-associated steatotic liver disease were examined. Patients were divided into two groups based on the presence of concomitant coronary artery disease: group

APA, Harvard, Vancouver, ISO, and other styles

16

Swanson, Gregory P., Steven Stone, Lauren Lenz, and Todd Cohen. "Ability of cell-cycle progression score to predict risk for progression to metastatic disease and disease-specific mortality in prostate cancer patients after prostatectomy." Journal of Clinical Oncology 38, no. 15_suppl (2020): 5524. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.5524.

Full text

Abstract:

5524 Background: Prostate cancer treatment aims to prevent metastatic disease (METS) and disease-specific mortality (DSM). A major challenge is to identify those at highest risk so additional intervention can be initiated earlier when it has a better chance of success. Pathologic parameters alone have limited ability to predict METS and DSM, but data suggests biomarkers can improve risk discrimination. Methods: Eligible patients had: (1) prostate cancer treated with radical prostatectomy (RP; 1988-1995); (2) available tissue for cell-cycle progression (CCP) testing that resulted in a valid sco

APA, Harvard, Vancouver, ISO, and other styles

17

Wang, Linbo, Wei Cheng, Edmund T. Rolls, et al. "Association of specific biotypes in patients with Parkinson disease and disease progression." Neurology 95, no. 11 (2020): e1445-e1460. http://dx.doi.org/10.1212/wnl.0000000000010498.

Full text

Abstract:

ObjectiveTo identify biotypes in patients with newly diagnosed Parkinson disease (PD) and to test whether these biotypes could explain interindividual differences in longitudinal progression.MethodsIn this longitudinal analysis, we use a data-driven approach clustering PD patients from the Parkinson's Progression Markers Initiative (n = 314, age 61.0 ± 9.5, years 34.1% female, 5 years of follow-up). Voxel-level neuroanatomic features were estimated with deformation-based morphometry (DBM) of T1-weighted MRI. Voxels with deformation values that were significantly correlated (p < 0.01) with c

APA, Harvard, Vancouver, ISO, and other styles

18

Lipshitz, Jay, Sewanti Limaye, and Dilip Patel. "Leukocyte Alkaline Phosphatase Score as a Marker of Severity and Progression of Myelodysplastic Syndrome." Blood 110, no. 11 (2007): 4625. http://dx.doi.org/10.1182/blood.v110.11.4625.4625.

Full text

Abstract:

Abstract Leukocyte Alkaline Phosphatase (LAP) Score is valuable in the work-up of certain hematological diseases. Most notably, the score is decreased in Chronic Myelogenous Leukemia and Paraoxysmal Nocturnal Hemaglobinurea but increased in leukemoid reaction to infection and Polycythemia Vera. Last year we reported the LAP scores of 14 patients with Myelodysplastic Syndrome (MDS). Our results showed that patients with less than 5% bone marrow blasts had significantly higher LAP scores than patients with 5–19% bone marrow blasts. We raised the possibility that LAP scores decrease as MDS progre

APA, Harvard, Vancouver, ISO, and other styles

19

Markusse, Iris M., Linda Dirven, Marianne van den Broek, et al. "A Multibiomarker Disease Activity Score for Rheumatoid Arthritis Predicts Radiographic Joint Damage in the BeSt Study." Journal of Rheumatology 41, no. 11 (2014): 2114–19. http://dx.doi.org/10.3899/jrheum.131412.

Full text

Abstract:

Objective.To determine whether a multibiomarker disease activity (MBDA) score predicts radiographic damage progression in the subsequent year in patients with early rheumatoid arthritis.Methods.There were 180 serum samples available in the BeSt study (trial numbers NTR262, NTR 265): 91 at baseline (84 with radiographs available) and 89 at 1-year followup (81 with radiographs available). Radiographs were assessed using the Sharp/van der Heijde Score (SvdH). Twelve serum biomarkers were measured to determine MBDA scores using a validated algorithm. Receiver-operating curves and Poisson regressio

APA, Harvard, Vancouver, ISO, and other styles

20

Kobayakawa, Yuko, Senri Ko, Takumi Tashiro, et al. "FVC-DiP correlates with neurofilament light chain levels in serum and cerebrospinal fluid in patients with ALS." BMJ Neurology Open 7, no. 1 (2025): e001012. https://doi.org/10.1136/bmjno-2024-001012.

Full text

Abstract:

BackgroundWe previously reported a scale to assess the disease progression rate in patients with amyotrophic lateral sclerosis (ALS), the forced vital capacity decline pattern scale (FVC-DiP). In this study, we investigated the association between FVC-DiP scores and neurofilament light chain (NfL) in the serum and cerebrospinal fluid (CSF) in patients with ALS.MethodsWe performed a retrospective study to examine the association between NfL levels and the rate of disease progression (N=41). The disease progression rate was assessed using three methods: the FVC-DiP score determined using the per

APA, Harvard, Vancouver, ISO, and other styles

21

Lee, David J., Tarek Ajami, Hui Yu, et al. "Grade and volume progression and its association with the Decipher genomic classifier using patients enrolled in a prospective active surveillance protocol." Journal of Clinical Oncology 43, no. 5_suppl (2025): 262. https://doi.org/10.1200/jco.2025.43.5_suppl.262.

Full text

Abstract:

262 Background: The progression of prostate cancer through serial biopsies in patients on active surveillance is a multifaceted process, with grade and volume progression offering unique perspectives on disease advancement. The Decipher genomic classifier has been recognized as a valuable tool for predicting disease progression. This study examines the relationship between the Decipher score, and other GRID signatures and pathways, and grade and volume progression in prostate cancer patients, utilizing data collected prospectively from the Miami Active Surveillance Trial (MAST). Methods: We sc

APA, Harvard, Vancouver, ISO, and other styles

22

Jehn, Lutz B., Ulrich Costabel, Eda Boerner, et al. "Serum KL-6 as a Biomarker of Progression at Any Time in Fibrotic Interstitial Lung Disease." Journal of Clinical Medicine 12, no. 3 (2023): 1173. http://dx.doi.org/10.3390/jcm12031173.

Full text

Abstract:

The development of a progressive phenotype of interstitial lung disease (ILD) is still unpredictable. Whereas tools to predict mortality in ILD exist, scores to predict disease progression are missing. The aim of this study was to investigate whether baseline serum KL-6 as an established marker to assess disease activity in ILD, alone or in combination with clinical variables, could improve stratification of ILD patients according to progression risk at any time. Consecutive patients with fibrotic ILD, followed at our institution between 2008 and 2015, were investigated. Disease progression wa

APA, Harvard, Vancouver, ISO, and other styles

23

Scelsi, Marzia A., Raiyan R. Khan, Marco Lorenzi, et al. "Genetic study of multimodal imaging Alzheimer’s disease progression score implicates novel loci." Brain 141, no. 7 (2018): 2167–80. http://dx.doi.org/10.1093/brain/awy141.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

EPSTEIN, JONATHAN I., CHARLES R. POUND, ALAN W. PARTIN, and PATRICK C. WALSH. "DISEASE PROGRESSION FOLLOWING RADICAL PROSTATECTOMY IN MEN WITH GLEASON SCORE 7 TUMOR." Journal of Urology 160, no. 1 (1998): 97–101. http://dx.doi.org/10.1016/s0022-5347(01)63045-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Rossetti, Heidi C., C. Munro Cullum, Linda S. Hynan, and Laura H. Lacritz. "The CERAD Neuropsychologic Battery Total Score and the Progression of Alzheimer Disease." Alzheimer Disease & Associated Disorders 24, no. 2 (2010): 138–42. http://dx.doi.org/10.1097/wad.0b013e3181b76415.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Migliorelli, Carolina, Meritxell Gómez-Martinez, Paula Subías-Beltrán, et al. "Multidimensional Biomechanics-Based Score to Assess Disease Progression in Duchenne Muscular Dystrophy." Sensors 23, no. 2 (2023): 831. http://dx.doi.org/10.3390/s23020831.

Full text

Abstract:

(1) Background: Duchenne (DMD) is a rare neuromuscular disease that progressively weakens muscles, which severely impairs gait capacity. The Six Minute-Walk Test (6MWT), which is commonly used to evaluate and monitor the disease’s evolution, presents significant variability due to extrinsic factors such as patient motivation, fatigue, and learning effects. Therefore, there is a clear need for the establishment of precise clinical endpoints to measure patient mobility. (2) Methods: A novel score (6M+ and 2M+) is proposed, which is derived from the use of a new portable monitoring system capable

APA, Harvard, Vancouver, ISO, and other styles

27

Kang, Min Kyoung, Jung Hwan Shin, Tae Jung Kim, Ji Sung Lee, Byung-Woo Yoon, and Sang-Bae Ko. "Use of proton pump inhibitor may be associated with progression of cerebral small vessel disease." PLOS ONE 17, no. 12 (2022): e0279257. http://dx.doi.org/10.1371/journal.pone.0279257.

Full text

Abstract:

Proton pump inhibitors (PPIs) are widely used for the treatment of gastrointestinal diseases. However, recent studies have shown that chronic PPI use is associated with the progression of endothelial senescence and cerebrovascular diseases. We hypothesized that PPI users might be vulnerable to fast progression of cerebral small vessel disease (SVD) with cumulative effects. Four hundred and eleven patients, who underwent brain magnetic resonance imaging, more than twice between January 2010 and December 2016 were screened. Patients aged < 50 years, and those who had concomitant diseases that

APA, Harvard, Vancouver, ISO, and other styles

28

Bergamaschi, Roberto, Silvana Quaglini, Eleonora Tavazzi, et al. "Immunomodulatory therapies delay disease progression in multiple sclerosis." Multiple Sclerosis Journal 22, no. 13 (2016): 1732–40. http://dx.doi.org/10.1177/1352458512445941.

Full text

Abstract:

Background: Few studies have analysed long-term effects of immunomodulatory disease modifying drugs (DMDs). Objective: Assessment of the efficacy of DMDs on long-term evolution of multiple sclerosis, using a Bayesian approach to overcome methodological problems related to open-label studies. Methods: MS patients from three different Italian multiple sclerosis centres were divided into subgroups according to the presence of treatment in their disease history before the endpoint, which was represented by secondary progression. Patients were stratified on the basis of the risk score BREMS (Bayesi

APA, Harvard, Vancouver, ISO, and other styles

29

Segala, Francesco Vladimiro, Emanuele Rando, Federica Salvati, et al. "Anakinra in hospitalized COVID-19 patients guided by baseline soluble urokinase plasminogen receptor plasma levels: A real world, retrospective cohort study." PLOS ONE 18, no. 4 (2023): e0273202. http://dx.doi.org/10.1371/journal.pone.0273202.

Full text

Abstract:

Background In patients with COVID-19 and baseline soluble urokinase plasminogen receptor plasma (suPAR) levels ≥ 6ng/mL, early administration of anakinra, a recombinant interleukin-1 receptor antagonist, may prevent disease progression and death. In case of suPAR testing unavailability, the Severe COvid Prediction Estimate (SCOPE) score may be used as an alternative in guiding treatment decisions. Methods We conducted a monocenter, retrospective cohort study, including patients with SARS-CoV2 infection and respiratory failure. Patients treated with anakinra (anakinra group, AG) were compared t

APA, Harvard, Vancouver, ISO, and other styles

30

Tsai, Tsung-Ying, Pai-Feng Hsu, Cheng-Hsueh Wu, et al. "Association between Coronary Artery Plaque Progression and Liver Fibrosis Biomarkers in Population with Low Calcium Scores." Nutrients 14, no. 15 (2022): 3163. http://dx.doi.org/10.3390/nu14153163.

Full text

Abstract:

Background: The severity of nonalcoholic fatty liver disease (NAFLD) has been found to be associated with atherosclerosis burden. However, whether liver fibrosis scores can be used to predict atherosclerosis progression, especially for patients with low calcium scores, remains undetermined. Methods: A total of 165 subjects who underwent repeated coronary computed tomography angiography (CCTA) and had low calcium scores (<100) were enrolled. The segment stenosis score (SSS) from the CCTA was measured, and the association between SSS progression and biochemical parameters was analyzed in addi

APA, Harvard, Vancouver, ISO, and other styles

31

Pavicic, Mirko, Kirk Overmyer, Attiq ur Rehman, Piet Jones, Daniel Jacobson, and Kristiina Himanen. "Image-Based Methods to Score Fungal Pathogen Symptom Progression and Severity in Excised Arabidopsis Leaves." Plants 10, no. 1 (2021): 158. http://dx.doi.org/10.3390/plants10010158.

Full text

Abstract:

Image-based symptom scoring of plant diseases is a powerful tool for associating disease resistance with plant genotypes. Advancements in technology have enabled new imaging and image processing strategies for statistical analysis of time-course experiments. There are several tools available for analyzing symptoms on leaves and fruits of crop plants, but only a few are available for the model plant Arabidopsis thaliana (Arabidopsis). Arabidopsis and the model fungus Botrytis cinerea (Botrytis) comprise a potent model pathosystem for the identification of signaling pathways conferring immunity

APA, Harvard, Vancouver, ISO, and other styles

32

Ham, Young Rok, Eu Jin Lee, Hae Ri Kim, et al. "Ultrasound Renal Score to Predict the Renal Disease Prognosis in Patients with Diabetic Kidney Disease: An Investigative Study." Diagnostics 13, no. 3 (2023): 515. http://dx.doi.org/10.3390/diagnostics13030515.

Full text

Abstract:

Renal disease associated with type 2 diabetes mellitus (T2DM) has become the leading cause of chronic kidney disease (CKD). Renal ultrasonography is an imaging examination required in the work-up of renal disease. This study aimed to identify the differences in renal ultrasonographic findings between patients with and without DM, and to evaluate the relationship between renal ultrasound findings and renal prognosis in patients with DM. A total of 252 patients who underwent renal ultrasonography at Chungnam National University Hospital were included. Kidney disease progression was defined as a

APA, Harvard, Vancouver, ISO, and other styles

33

Chenniappan, Raghavi, Hanumanthappa Nandeesha, Shivanand Kattimani, and Nandakumar Dalavaikodihalli Nanjaiah. "Interleukin-17 and Interleukin-10 Association with Disease Progression in Schizophrenia." Annals of Neurosciences 27, no. 1 (2020): 24–28. http://dx.doi.org/10.1177/0972753120929565.

Full text

Abstract:

Background: Alteration in cytokine levels are known to be involved in the pathogenesis of schizophrenia. Objectives: To estimate the serum levels of interleukin-17 (IL-17) and interleukin-10 (IL-10) and their association with disease progression in schizophrenia. Methods: A total of 67 schizophrenia cases were enrolled in the present study. IL-17 and IL-10 were estimated by enzyme-linked immunosorbent assay. Positive and Negative Syndrome Scale (PANSS) was used to evaluate disease severity. Results: IL-17 was positively correlated with positive symptom score ( r = 0.256, p = .036), general psy

APA, Harvard, Vancouver, ISO, and other styles

34

Tommasino, Antonella, Federico Dell’Aquila, Marco Redivo, et al. "Comprehensive Risk Assessment of LAD Disease Progression in CCTA: The CLAP Score Study." Journal of Cardiovascular Development and Disease 11, no. 11 (2024): 338. http://dx.doi.org/10.3390/jcdd11110338.

Full text

Abstract:

Background: a wider left main bifurcation angle (LMBA) has been linked to severe plaque development in the proximal left anterior descending artery (LAD). This study aimed to identify predictors of severe proximal LAD stenosis and major adverse cardiovascular events (MACE) using coronary computed tomography angiography (CCTA). Methods: from an initial cohort of 650 consecutive patients, we analyzed 499 patients who met the inclusion criteria after exclusions. Plaque morphology and characteristics were assessed by CCTA, and MACE occurrences were recorded at follow-up. A predictive score for LAD

APA, Harvard, Vancouver, ISO, and other styles

35

Rossi, Silvia, Fabio Buttari, Valeria Studer, et al. "The (AAT)n repeat of the cannabinoid CB1 receptor gene influences disease progression in relapsing multiple sclerosis." Multiple Sclerosis Journal 17, no. 3 (2010): 281–88. http://dx.doi.org/10.1177/1352458510388680.

Full text

Abstract:

Background: Genetic and pharmacological inactivation of cannabinoid CB1 receptors (CB1Rs) exacerbates disease course in experimental autoimmune encephalomyelitis, suggesting that CB1Rs might play a role in the neurodegenerative damage associated with multiple sclerosis (MS). Objectives: To see whether CNR1 gene polymorphism could influence disease progression in relapsing–remitting MS. Methods: The genotype of 350 patients for the number of AAT repeats was characterized and correlation studies were performed with measures of disease severity and progression. Results: MS patients with the homoz

APA, Harvard, Vancouver, ISO, and other styles

36

Umemoto, George, Shinsuke Fujioka, Yasuyuki Iwasa, et al. "Impact of Progression of Parkinson’s Disease on Swallowing Ability and Oral Environment." Parkinson's Disease 2021 (April 23, 2021): 1–6. http://dx.doi.org/10.1155/2021/5571556.

Full text

Abstract:

This study investigated the impact of the severity and treatment of Parkinson’s disease (PD) on the swallowing ability and oral environment of patients. Swallowing dysfunction increases the aspiration risk and may lead to poor oral health among patients with PD. We investigated the influences of PD progression and drug treatment on the swallowing ability and oral environment using simple noninvasive screening measurements. We recruited 87 patients with PD (mean age, 71.9 ± 8.0 years; mean Hoehn and Yahr score, 2.9 ± 0.9). The PD condition was assessed in each patient using the unified Parkinso

APA, Harvard, Vancouver, ISO, and other styles

37

Xie, Linjun, Keke Hou, Huayan Xu, et al. "Chest CT features and progression of patients with coronavirus disease 2019." British Journal of Radiology 93, no. 1116 (2020): 20200219. http://dx.doi.org/10.1259/bjr.20200219.

Full text

Abstract:

Objectives: Coronavirus disease 2019 (COVID-19) is a major public health emergency. It poses a grave threat to human life and health. The purpose of the study is to investigate the chest CT findings and progression of the disease observed in COVID-19 patients. Methods: Forty-nine confirmed cases of adult COVID-19 patients with common type, severe and critically severe type were included in this retrospective single-center study. The thin-section chest CT features and progress of the disease were evaluated. The clinical and chest imaging findings of COVID-19 patients with different severity typ

APA, Harvard, Vancouver, ISO, and other styles

38

Chen, Szu-Ju, Yu-Chiao Chi, Chang-Han Ho, Wei-Shiung Yang, and Chin-Hsien Lin. "Plasma Lipopolysaccharide-Binding Protein Reflects Risk and Progression of Parkinson’s Disease." Journal of Parkinson's Disease 11, no. 3 (2021): 1129–39. http://dx.doi.org/10.3233/jpd-212574.

Full text

Abstract:

Background: Lipopolysaccharide-binding protein (LBP) presents bacterial endotoxin, lipopolysaccharides, to cellular surface pattern receptors for immune responses in the gut-brain axis of Parkinson’s disease (PD). Objective: We investigated whether plasma LBP levels were associated with PD severity and progression. Methods: This study included 397 participants (248 PD patients and 149 controls). We measured participants’ plasma levels of LBP and pro-inflammatory cytokines, including TNF-α, IL-6, andIL-17A. PD patients underwent motor and cognition evaluations at baseline and at a mean follow-u

APA, Harvard, Vancouver, ISO, and other styles

39

Porcaro, Antonio Benito, Rossella Orlando, Andrea Panunzio, et al. "Preoperative Briganti Nomogram Score and Risk of Prostate Cancer Progression After Robotic Surgery Beyond EAU Risk Categories." Medicina 60, no. 11 (2024): 1763. http://dx.doi.org/10.3390/medicina60111763.

Full text

Abstract:

Background and Objectives: We sought to investigate whether the 2012 Briganti nomogram may represent a potential prognostic factor of prostate cancer (PCa) progression after surgical treatment beyond European Association of Urology (EAU) risk categories. Materials and Methods: From January 2013 to December 2021, data on PCa patients treated with robot-assisted radical prostatectomy at a single tertiary referral center were extracted. The 2012 version of the Briganti nomogram assessing the risk of pelvic lymph node invasion was used. Here, the nomogram score was evaluated both as a continuous a

APA, Harvard, Vancouver, ISO, and other styles

40

Gautam, Sachin, Rahul Kumar, Dharam Pal Bhadoria, et al. "Clinical profile of hospitalised moderate category COVID-19 patients: Short study from a Tertiary Care Centre in Delhi." Journal of Family Medicine and Primary Care 12, no. 8 (2023): 1644–53. http://dx.doi.org/10.4103/jfmpc.jfmpc_2245_22.

Full text

Abstract:

Background: The clinical profile of hospitalized moderate-category COVID-19 patients has been understudied globally and in India. Aim: The present study was conducted to study the clinical profile and assess the proportions of patients who progressed to severe disease and its predictors among moderate COVID-19 patients. Materials and Methods: In this single-center observational study, 100 moderate-category COVID-19 patients as per Ministry of Health and Family Welfare (MoHFW) criteria of age ≥18 years of either sex, excluding pregnant females from February to November 2021, were studied by ana

APA, Harvard, Vancouver, ISO, and other styles

41

Gao, Yang, Hong-Liang Zhang, Meiying Xin, et al. "Serum Folate Correlates with Severity of Guillain-Barré Syndrome and Predicts Disease Progression." BioMed Research International 2018 (June 14, 2018): 1–5. http://dx.doi.org/10.1155/2018/5703279.

Full text

Abstract:

The aim of this study was to determine the associations between serum folate level and the clinical course and severity of Guillain-Barré syndrome (GBS). We retrospectively enrolled 112 pairs of GBS patients and age- and sex-matched healthy controls with measured serum folate levels. On admission, 21 (18.9%) GBS patients had folate deficiency, of which only two were female patients. Patients with normal folate levels had a shorter disease progression than those with folate deficiency (median progression duration: 6 versus 13 days, p < 0.001). Serum folate levels on admission were correlated

APA, Harvard, Vancouver, ISO, and other styles

42

Jedynak, Bruno M., Andrew Lang, Bo Liu, et al. "A computational neurodegenerative disease progression score: Method and results with the Alzheimer's disease neuroimaging initiative cohort." NeuroImage 63, no. 3 (2012): 1478–86. http://dx.doi.org/10.1016/j.neuroimage.2012.07.059.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Castillo, Irene, Francis Rossignol, Kristen Pan, et al. "P021: Development of a radiographic vertebral disease severity score for evaluation of disease progression in alkaptonuria." Genetics in Medicine Open 3 (2025): 102865. https://doi.org/10.1016/j.gimo.2025.102865.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

He, Runcheng, Yuwen Zhao, Yan He, et al. "Olfactory Dysfunction Predicts Disease Progression in Parkinson’s Disease: A Longitudinal Study." Frontiers in Neuroscience 14 (December 14, 2020). http://dx.doi.org/10.3389/fnins.2020.569777.

Full text

Abstract:

Background and Objective:Olfactory dysfunction (hyposmia) is an important non-motor symptom of Parkinson’s disease (PD). To investigate the potential prognostic value of hyposmia as a marker for disease progression, we prospectively assessed clinical manifestations and longitudinal changes of hyposmic PD patients and normosmic ones.MethodsOlfactory function was evaluated with the Sniffin’ Sticks in PD patients at baseline. One hundred five hyposmic PD patients and 59 normosmic PD patients were enrolled and followed up for 2 years. They were subsequently evaluated at baseline and during follow-

APA, Harvard, Vancouver, ISO, and other styles

45

Youssef, Hossam, Mutlu Demirer, Erik H. Middlebrooks, Bhrugun Anisetti, James F. Meschia, and Michelle P. Lin. "Framingham Stroke Risk Profile Score and White Matter Disease Progression." Neurologist, June 13, 2024. http://dx.doi.org/10.1097/nrl.0000000000000567.

Full text

Abstract:

Objectives: To evaluate the relationship between Framingham Stroke Risk Profile (FSRP) score and rate of white matter hyperintensity (WMH) progression and cognition. Methods: Consecutive patients enrolled in the Mayo Clinic Florida Familial Cerebrovascular Diseases Registry (2011-2020) with 2 brain-MRI scans at least 1 year apart were included. The primary outcome was annual change in WMH volume (cm3/year) stratified as fast versus slow (above vs. below median). Cognition was assessed using a Mini-Mental State Exam (MMSE, 0-30). FSRP score (0 to 8) was calculated by summing the presence of age

APA, Harvard, Vancouver, ISO, and other styles

46

Liu, Peng, Linxi Chen, Xinwei He, and Lingqun Mao. "Predictors of the rapid progression in prodromal Parkinson’s disease: a longitudinal follow-up study." Gerontology, April 2, 2024. http://dx.doi.org/10.1159/000538515.

Full text

Abstract:

Introduction: Parkinson's disease (PD) is characterized by a prodromal phase preceding the onset of classic motor symptoms. The duration and clinical manifestations of prodromal PD vary widely, indicating underlying heterogeneity within this stage. This discrepancy prompts the question of whether specific factors contribute to the divergent rates of progression in prodromal PD. Methods: This study included prodromal PD patients from the Parkinson’s Progression Markers Initiative. They were followed up to assess the disease progression. The data collected during the follow-up period were analyz

APA, Harvard, Vancouver, ISO, and other styles

47

Deng, Xiao, Seyed Ehsan Saffari, Bin Xiao, et al. "Disease Progression of Data-Driven Subtypes of Parkinson’s Disease: 5-Year Longitudinal Study from the Early Parkinson’s disease Longitudinal Singapore (PALS) Cohort." Journal of Parkinson's Disease, June 5, 2024, 1–9. http://dx.doi.org/10.3233/jpd-230209.

Full text

Abstract:

Background: The detailed trajectory of data-driven subtypes in Parkinson’s disease (PD) within Asian cohorts remains undisclosed. Objective: To evaluate the motor, non-motor symptom (NMS) progression among the data-driven PD clusters. Methods: In this 5-year longitudinal study, NMS scale (NMSS), Hospital Anxiety Depression Scale (HADS), and Epworth sleepiness scale (ESS) were carried out annually to monitor NMS progression. H& Y staging scale, MDS-UPDRS part III motor score, and postural instability gait difficulty (PIGD) score were assessed annually to evaluate disease severity and motor

APA, Harvard, Vancouver, ISO, and other styles

48

Bhattacharya, Souvik. "Evaluating Score Based Disease Progression Using Item Response Theory." Journal of pharmacology & clinical research 2, no. 3 (2017). http://dx.doi.org/10.19080/jpcr.2017.02.555587.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Río Bártulos, Carolina, Karin Senk, Ragnar Bade, et al. "Using AI and Gd-EOB-DTPA-enhanced MR imaging to assess liver function, comparing the MELIF score with the ALBI score." Scientific Reports 13, no. 1 (2023). http://dx.doi.org/10.1038/s41598-023-39954-1.

Full text

Abstract:

AbstractMonitoring disease progression is particularly important for determining the optimal treatment strategy in patients with liver disease. Especially for patients with diseases that have a reversible course, there is a lack of suitable tools for monitoring liver function. The development and establishment of such tools is very important, especially in view of the expected increase in such diseases in the future. Image-based liver function parameters, such as the T1 relaxometry-based MELIF score, are ideally suited for this purpose. The determination of this new liver function score is ful

APA, Harvard, Vancouver, ISO, and other styles

50

Peraza, Jellyana, Marco Emilio Kaper, Andre Bargas, et al. "A Simple Endoscopic Score for Crohn's Disease (SES‐CD) ≥ 7 Predicts Disease Progression." Alimentary Pharmacology & Therapeutics, January 5, 2025. https://doi.org/10.1111/apt.18492.

Full text

Abstract:

ABSTRACTBackgroundUp to 30% of patients with Crohn's disease (CD) will experience a mild disease course. However, there is no consensus definition for mild CD.AimTo examine the Simple Endoscopic Score for Crohn's disease (SES‐CD) thresholds best associated with low likelihood of long‐term disease progression.MethodsWe conducted a multicentre retrospective cohort study at three tertiary care centres in United States and Europe. We analysed data from 177 surgery‐naïve patients with CD who had endoscopic assessment while not on immunosuppressive therapy. The primary outcome was disease progressio

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!